BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release titled "University of Glasgow Officially Opens Mazumdar Shaw Advance Research Centre"09-06-2022
09-06-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meeting08-06-2022
Biocon chief Kiran Majumdar-Shaw slams poor condition of Bengaluru roads
The arterial roads which are dug for various civic works are not being repaired. The potholes have resulted in several deaths in Bengaluru, triggering public outrage.07-06-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meeting03-06-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor Meeting31-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting26-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings26-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet24-05-2022
CCI approves merger by absorption of Covidshield Technologies into Biocon Biologics
The Competition Commission of India (CCI) on Thursday approved merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences.19-05-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release titled 'Biocon Biologics and Viatris Launch Abevmy(r) (bBevacizumab), Their Third Oncology Biosimilar, in Canada'.19-05-2022